menu
    • menu
    [{"orgOrder":0,"company":"AbViro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbViro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbViro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbViro \/ Undisclosed"},{"orgOrder":0,"company":"AbViro","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid||Undisclosed","graph1":"Undisclosed","graph2":"Phase II","graph3":"AbViro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AbViro \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"8","companyTruncated":"AbViro \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Neurology","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Life Molecular Imaging \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ Undisclosed"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ pharmtrace"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"Bayer AG | National Institute on Aging","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Neurology","graph2":"Undisclosed","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ Bayer AG | National Institute on Aging","highestDevelopmentStatusID":"1","companyTruncated":"New York State Psychiatric Institute \/ Bayer AG | National Institute on Aging"}]

    Find Clinical Drug Pipeline Developments & Deals for Florbetaben

    Menu

    Florbetaben

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbViro

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AbViro

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

                            Details : AV-1 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 29, 2025

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Life Molecular Imaging

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : pharmtrace

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Test-retest Study With [18F]FBB in Cardiac Amyloidosis

                            Details : Florbetaben is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Amyloidosis, Hereditary, Transthyretin-Related.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 24, 2025

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : pharmtrace

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbViro

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            AbViro

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volun...

                            Details : AV-1 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2020

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : National Institute of Allergy and Infectious Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            New York State Psychiatric Institute

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            New York State Psychiatric Institute

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Bayer AG | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

                            Details : Florbetaben is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 18, 2010

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Bayer AG | National Institute on Aging

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Life Molecular Imaging

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Life Molecular Imaging

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patient...

                            Details : Florbetaben is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 07, 2010

                            Lead Product(s) : Florbetaben

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth